Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Position Lessened by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 60.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,200 shares of the biopharmaceutical company's stock after selling 253,287 shares during the period. Bridgeway Capital Management LLC owned approximately 0.29% of Vanda Pharmaceuticals worth $796,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at $69,000. Zacks Investment Management purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth about $74,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 3,370 shares during the period. Tudor Investment Corp ET AL grew its stake in shares of Vanda Pharmaceuticals by 59.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company's stock valued at $118,000 after buying an additional 9,180 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 5,459 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Wall Street Analyst Weigh In

VNDA has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a "hold" rating for the company. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Insiders Place Their Bets

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were bought at an average price of $5.02 per share, with a total value of $50,200.00. Following the acquisition, the chief executive officer now directly owns 2,285,731 shares in the company, valued at approximately $11,474,369.62. This represents a 0.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought a total of 32,000 shares of company stock valued at $151,180 in the last quarter. Insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Trading Up 5.9%

NASDAQ VNDA traded up $0.23 during mid-day trading on Friday, reaching $4.16. 732,654 shares of the company's stock traded hands, compared to its average volume of 723,526. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $6.75. The company has a fifty day simple moving average of $4.43 and a 200-day simple moving average of $4.63. The company has a market cap of $245.17 million, a price-to-earnings ratio of -13.00 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.